Regenxbio (RGNX) Misses Q3 EPS by 5c

Regenxbio (NASDAQ: RGNX) reported Q3 EPS of ($1.17), $0.05 worse than the analyst estimate of ($1.12). Revenue for the quarter came in at $24.19 million versus the consensus estimate of $23.63 million.

For earnings history and earnings-related data on Regenxbio (RGNX) click here.

You May Also Be Interested In

• Kalshi in early talks for IPO - The Information
• Alamos Gold Inc. (AGI:CN) (AGI) PT Lowered to Cdn$73 at BMO Capital
• Blue Star Gold closes final tranche of flow-through private placement